

**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**

**DIRECTORS' REPORT**

Your directors present the financial accounts of the company for the year ended 31 March 2025.

**Directors**

The names of the directors in office at the date of this report are:

Alakkudi Sundararaman  
Kavita Sehwan

**Principal Activities**

The principal activities of the company in the course of the year were:

Reg'n & cloning of pharmaceutical products with TGA-Aust.

No significant change in the nature of these activities occurred during the year.

**Results**

The net profit of the company for the financial year after providing for income tax amounted to \$0.

**Dividends paid or recommended**

No dividends were paid or declared since the start of the financial year. No recommendation is made as to dividends.

*Sundararaman*

### Directors Benefits

No director has The director has not received or become entitled to receive, during or since the financial year, a benefit because of a contract made by the company or a related body corporate with the director, a firm of which the director is a member or an entity in which the director has a substantial interest.

This statement excludes a benefit included in the aggregate amount of emoluments received, or due and receivable, by directors as shown in the company's financial accounts for the financial year or the fixed salary of a full-time employee of the company or a related body corporate.

### Indemnifying Officer or Auditor

The company has not, during or since the financial year, in respect of any person who is or has been an officer or auditor of the company or of a related body corporate:

- (a) indemnified or made any relevant agreement for indemnifying against a liability incurred as an officer or auditor, including costs and expenses in successfully defending legal proceedings; or
- (b) paid or agreed to pay a premium in respect of a contract insuring against a liability incurred as an officer or auditor for the costs or expenses to defend legal proceedings.


Signed in accordance with a resolution of the Board of Directors:

Director



Alakkudi Sundararaman

Director



Kavita Schwani

Dated this 27 day of May, 2025

**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**

**PROFIT AND LOSS ACCOUNT**  
**FOR THE YEAR ENDED 31 MARCH 2025**

	YTDMAR25	YTDMAR24
	NOTE	\$
<b>INCOME</b>		
Sundry Income	182221	188530
<b>EXPENSES</b>		
Accountancy	5820	3381
Auditors Remuneration - Fees	3000	-
Bank Charges	132	144
Courier Fees	90	250
Filing Fees	310	290
Registration Fees	172869	184465
<b>TOTAL EXPENSES</b>	182221	188530
<b>OPERATING PROFIT AND EXTRAORDINARY ITEMS</b>	-	-
Retained Profits at April 1	91689	91689
<b>PROFIT AVAILABLE FOR APPROPRIATION</b>	91689	91689
<b>RETAINED PROFITS</b>	91689	91689

*Singh Anand*

The accompanying notes form part of these  
financial statements  
These statements are unaudited and should be read in  
conjunction with the attached compilation report

**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**

**BALANCE SHEET**  
**AS AT 31 MARCH 2025**

	NOTE	YTDMAR25 \$	YTDMAR24 \$
<b>CURRENT ASSETS</b>			
Cash		13502	9702
Receivables	2	14933	19104
Other		441	70
<b>TOTAL CURRENT ASSETS</b>		<u>28876</u>	<u>28876</u>
<b>NON-CURRENT ASSETS</b>			
Investments	3	87	87
Intangibles		77156	77156
Other		12514	12514
<b>TOTAL NON-CURRENT ASSETS</b>		<u>89757</u>	<u>89757</u>
<b>TOTAL ASSETS</b>		<u>118633</u>	<u>118633</u>
<b>CURRENT LIABILITIES</b>			
<b>TOTAL CURRENT LIABILITIES</b>		<u>-</u>	<u>-</u>
<b>NON-CURRENT LIABILITIES</b>			
<b>TOTAL NON-CURRENT LIABILITIES</b>		<u>-</u>	<u>-</u>
<b>TOTAL LIABILITIES</b>		<u>-</u>	<u>-</u>
<b>NET ASSETS</b>		<u>118633</u>	<u>118633</u>
<b>EQUITY</b>			
Issued Capital		26944	26944
Accumulated Profit		91689	91689
<b>TOTAL EQUITY</b>		<u>118633</u>	<u>118633</u>

*Singawarara*

The accompanying notes form part of these  
financial statements  
These statements are unaudited and should be read in  
conjunction with the attached compilation report



**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**

**NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2025**

**NOTE 1 - STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES**

This financial report is a special purpose financial report prepared for use by the directors and member. The directors have determined that the company is not a reporting entity.

The financial report has been prepared in accordance with the requirements of the Corporations Law, and the following applicable Accounting Standards and other mandatory professional reporting requirements (Urgent Issues Group Consensus Views):

- AASB 1002: Events Occurring After Balance Date
- AASB 1018: Profit and Loss Accounts
- AASB 1025: Application of the Reporting Entity Concept and Other Amendments
- AASB 1031: Materiality
- AASB 1034: Information to be Disclosed in Financial Reports

No other applicable Accounting Standards or other mandatory professional reporting requirements (Urgent Issues Group Consensus Views) have been applied.

The statements have been prepared on an accruals basis. They are based on historical costs and do not take into account changing money values or, except where specifically stated, current valuations of non-current assets.

The following specific accounting policies, which are consistent with the previous period unless otherwise stated, have been adopted in the preparation of these statements:

*Singaraman*

These statements are unaudited and should be read in  
conjunction with the attached compilation report

**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**

**NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2025**

	YTDMAR25	YTDMAR24
	\$	\$
<b>NOTE 2 - RECEIVABLES</b>		
<b>Current</b>		
Accrued Reimbursements	12294	16465
Loan Subsidiary Companies		
Unsecured	2639	2639
	<u>14933</u>	<u>19104</u>
<b>NOTE 3 - INVESTMENTS</b>		
<b>Non Current</b>		
Shares in Subsidiary Companies		
at Cost	<u>87</u>	<u>87</u>

**NOTE 4 - RELATED PARTY DISCLOSURES**

During the year reimbursements of expenses from Ipca Laboratories Ltd included in Sundry Income was AUD 182,221 (previous period AUD 188,530).

At the year end an amount of AUD 12,294 (previous year AUD 16,465) owing from Ipca Laboratories Ltd for expense reimbursements was included in Receivables.

At the year end an amount of AUD 2,639 (previous period AUD 2,639) owing from Ipca Pharma (NZ) Pty Ltd was included in Receivables.

*Singharaman*

**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**

**NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2025**

**IPCA PHARMA (AUSTRALIA) PTY LTD**  
**A.C.N. 100 362 258**


**DIRECTORS' DECLARATION**


The directors have determined that the company is not a reporting entity. The directors have determined that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial statements.

The directors' of the company declare that:

1. the financial statements and notes, as set out in the accompanying accounts presents fairly the financial position as at 31 March 2025 and it's performance for the year ended on that date in accordance with the policies described in Note 1 to the financial statements;
2. in the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors:

Director   
Alakkudi Sundararaman

Director   
Kavita Schwani

Dated this 27 day of May 2025

## **COMPILATION REPORT TO IPCA PHARMA (AUSTRALIA) PTY LTD**

We have compiled the accompanying special purpose financial statements of IPCA PHARMA (AUSTRALIA) PTY LTD which comprise the balance sheet as at 31 March 2025, profit and loss statement for the year then ended, a summary of significant accounting policies and other explanatory notes.

The specific purpose for which the special purpose financial report has been prepared is to provide information relating to the performance and financial position of the company that satisfies the information needs of the directors.

### **The responsibility of the directors**

The directors are solely responsible for the information contained in the special purpose financial report and have determined that the basis of accounting used is appropriate to meet their needs and for the purpose for which the financial statements were prepared.

### **Our responsibility**

On the basis of information provided by the directors, we have compiled the accompanying special purpose financial statements in accordance with the financial reporting framework described in Note 1 to the financial statements and APES 315: Compilation of Financial Information.

Our procedures use accounting expertise to collect, classify and summarise the financial information, which the directors provided, into a financial report. Our procedures do not include verification or validation procedures. No audit or review has been performed and accordingly no assurance is expressed.

The special purpose financial report was prepared exclusively for the directors. We do not accept responsibility to any other person for the content of the special purpose financial statements.

### **Name of Firm:**

Pender & Associates Pty Ltd, Certified Practising Accountants

### **Name of Director:**



---

Thomas Joseph Pender

### **Address:**

Suite 4, Level 1, 474 Nepean Highway, Frankston, Victoria

### **Dated:**

9th May 2025